Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.

Literature DB >> 12558775

Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.

Abstract

Evidence based guidelines are presented on the selection and use of therapeutic products to treat haemophilia. These guidelines offer advice based on the best published scientific and medical information. They will be reviewed regularly by UKHCDO Advisory Committee. Included are details of therapeutic products available in the UK to treat patients with haemophilia and other bleeding disorders and the background information on which the recommendations are based are presented.

Entities: Disease Species

Mesh：

Substances：

Year: 2003 PMID： 12558775 DOI： 10.1046/j.1365-2516.2003.00711.x

Source DB: PubMed Journal: Haemophilia ISSN： 1351-8216 Impact factor: 4.287

Keyword Cloud
Cited

18 in total

Review 1. Octocog alfa, plasma/albumin-free method.

Authors: Paul L McCormack; Greg L Plosker
Journal: Drugs Date: 2005 Impact factor: 9.546

Review 2. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.

Authors: M Asif A Siddiqui; Lesley J Scott
Journal: Drugs Date: 2005 Impact factor: 9.546

Review 3. Recommendations for the transfusion of plasma and platelets.

Authors: Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal: Blood Transfus Date: 2009-04 Impact factor: 3.443

4. Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors: Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal: Blood Transfus Date: 2008-01 Impact factor: 3.443

9. Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.

Authors: Carrie A Thompson; Robert Kyle; Morie Gertz; John Heit; Rajiv Pruthi; Animesh Pardanani
Journal: Am J Hematol Date: 2010-03 Impact factor: 10.047

10. Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.

Authors: Steven Pipe
Journal: Biologics Date: 2009-07-13

Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.

Review 1. Octocog alfa, plasma/albumin-free method.

Review 2. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.

Review 3. Recommendations for the transfusion of plasma and platelets.

4. Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Review 5. Proteomics: applications in transfusion medicine.

Review 6. Immune tolerance induction for patients with severe hemophilia A: a critical literature review.

7. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates.

8. 7 Procoagulators.

9. Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.

10. Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.